

JOB OFFER		
REFERENCE	OPENING DATE	DEADLINE
2020.426	27/10/2023	05/11/2023
PROFILE REQUIREMENTS		
EXCLUSIVE REQUIREMENTS: (1)		
ACADEMIC DEGREE	Higher Degree in Pathological Anatomy - Cytodiagnostics ( <i>Exclusive requirement: provide justification with the application</i> ).	
VALUED MERITS /SKYLLS		
EXPERIENCE	<ul style="list-style-type: none"> <li>Minimum of 2 years experience in the management and handling of oncology clinical trial data.</li> <li>Computer and management applications.</li> <li>Experience in research projects.</li> </ul>	
LANGUAGES	<ul style="list-style-type: none"> <li>English</li> </ul>	
CONTRACT INFORMATION		
TYPE OF CONTRACT	EXPECTED INCORPORATION DATE	JOB STATUS
Indefinite in accordance with Article 23 Bis of Law 14/2011, of June 1, 2011, on Science, Technology and Innovation.	November/December 2023	Full-time 1800 hours per year (approx. 40 h/week)
ANNUAL GROSS SALARY	DURATION OF THE CONTRACT	
20.702,03 €	Indefinite, linked to the duration of the project and economic availability based on RDL8/2022	
WORK LOCATIONS	UNIT/DEPARTMENT	
Valdecilla South Building, 2nd Floor, Oncology Clinic	Medical Oncology Service. HUMV	
JOB DETAILS		
OFFER DESCRIPTION		
Research support technician		
FUNCTIONS		
<ul style="list-style-type: none"> <li>Management and handling of data required for oncology clinical trials.</li> <li>Data monitoring.</li> <li>Coordination with the whole team to achieve the deadlines set by the trials.</li> </ul>		
PRINCIPAL INVESTIGATOR / RESPONSABLE	RESEARCH GROUP	RESEARCH PROJECT
Fernando Rivera Herrero	Ensayos clínicos, Oncología Médica y Medicina paliativa	2023.123 A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) Estudio de fase 2, aleatorizado y abierto de botensilimab (AGEN1181) en monoterapia y en combinación con balstilimab (AGEN2034) o con el tratamiento de referencia elegido por el investigador (regorafenib o trifluridina y tipiracilo) para el tratamiento del cáncer colorrectal metastásico resistente. / AS MONOTHERAPY AND IN COMBINATION WITH BALSTILIMAB (AGEN2034) OR INVESTIGATOR'S CHOICE STANDARD OF CARE

		<b>(REGORAFENIB OR TRIFLURIDINE AND TIPIRACIL) FOR THE TREATMENT OF REFRACTORY METASTATIC COLORECTAL CANCER.</b>		
<b>RECRUITMENT INFORMATION</b>				
<b>SELECTION PROCESS STAGES (2)</b>				<b>EMPLOYMENT EXCHANGE</b>
<ol style="list-style-type: none"> <li>1. Pre-selection</li> <li>2. Interview: Minimum score for this phase: 45</li> <li>3. Report of the Selection Board</li> <li>4. Resolution</li> </ol>				<b>NOT</b>
<b>SELECTION BOARD</b>				
<ul style="list-style-type: none"> <li>• <b>Fernando Rivera Herrero, Project's Main Researcher</b></li> <li>• <b>Galo Peralta, IDIVAL's Management Director</b></li> <li>• <b>Patricia Álvarez-Ingelmo, IDIVAL Human Resources Coordinator (She will act as registrar of the selection board).</b></li> </ul>				
<b>VALUATION OF MERITS</b>				
MERITS	EVALUATION	SCORE		MAXIMUM
<b>Minimum of 2 years experience in the management and handling of oncology clinical trial data.</b>	<b>CV</b>	<b>Compliance with requirement</b>	<b>Yes/ Not</b>	<b>30</b>
<b>Computer and management applications.</b>	<b>CV</b>	<b>Compliance with requirement</b>	<b>Yes/ Not</b>	<b>5</b>
<b>Experience in research projects</b>	<b>CV</b>	<b>Compliance with requirement</b>	<b>Yes/ Not</b>	<b>10</b>
<b>English</b>	<b>CV</b>	<b>Compliance with requirement</b>	<b>-B1: 10 points -B2 or more: 15 points</b>	<b>15</b>
<b>FINAL SCORE</b>				
<b>MAXIMUM TOTAL SCORE BY MERITS</b>				<b>60</b>
<b>MAXIMUM TOTAL SCORE IN INTERVIEW</b>				<b>40</b>
<b>MAXIMUM TOTAL SCORE</b>				<b>100</b>

(1) Not subsanable

(2) See duration of each phase in the document "Selection Process"

*In compliance with the provisions of Article 11 of Organic Law 3/2018, you are informed that the person responsible for the processing of your personal data is the MARQUES DE VALDECILLA INSTITUTE OF INVESTIGATION FOUNDATION (IDIVAL), your data will be treated in order to be treated to the extent that they were necessary or convenient for the development of the legal relationship established between the parties. You can exercise your rights of access, rectification, deletion, opposition, portability or limitation of the treatment, by contacting the IDIVAL FOUNDATION at the following address: AVDA. CARDENAL HERRERA ORIA, S / N 39007, SANTANDER. More information at [www.idival.org/es/Política-de-Privacidad](http://www.idival.org/es/Política-de-Privacidad)*